Current Studies

Please click the trial name for more information.

Prostate Cancer

We offer clinical trials for patients newly diagnosed with prostate cancer and those who have received prior treatments as well. If you fall under one of these categories, please click on the studies below to learn more. Each trial is associated with a National Clinical Trial (NCT) number which links to ClinicalTrials.gov for more information about the study, sponsor, and criteria. All study related medications and tests are covered by Research.

New Diagnosis

Prostate Cancer Treatment (NCT06235151)

Summary: Diagnostic imaging trial to test the diagnostic performance of Cu-64 PSMA PET scan
in patients with newly diagnosed prostate cancer at unfavorable intermediate, high, and very high-risk levels.

Requirements for participation:

  • Male ≥18 years of age at the time of signing the informed consent
  • Newly diagnosed with prostate cancer

Not eligible if any of the following apply:

  • Received prior treatments/therapies for prostate cancer
  • Taken a PSMA-PET scan within 90 days of study enrollment

Biochemical Recurrence (BCR)

Prostate Cancer Treatment (NCT06235099)

Summary:Diagnostic imaging trial to test the diagnostic performance of Cu-64 PSMA PET scan in patients with recurring
prostate cancer post radiation therapy or radical prostatectomy.

Requirements for Participation:

  • Prior radiation therapy or radical prostatectomy for prostate cancer
  • Rising PSA as defined for biochemical recurrence of prostate cancer

Not eligible if any of the following apply: 

  • Currently on therapies that target the androgen pathway
  • Takena PSMA-PET scan within 90 days of study enrollment

Prostate Cancer Treatment (NCT06604442)

Summary: Diagnostic imaging trial to compare the radioactivity of Piflufolastat (18F) and Flotufolastat (18F) PET in patients with recurring prostate cancer with a previous treatment with radical prostatectomy.

Requirements for Participation:

  • Patients with biochemical recurrence after radical prostatectomy
  • Patients with low PSA values ≤ 0.5 ng/mL
  • Scheduled/recommended for PSMA (18F) PET scan for prostate cancer diagnosis

Not eligible if any of the following apply: 

  • Received radiation therapy or salvage therapy for prostate cancer
  • Received the Piflufolastat (18F) PSMA-PET scan

Prostate Cancer Treatment (NCT05059236)

Summary: Phase 3 study of Darolutamide(Nubeqa) and ADT or ADT alone for the treatment for high-risk biochemical
recurrent prostate cancer in patients that have received initial treatment for their cancer (i.e.Prostatectomy
(removal of prostate), prostatectomy and radiation, or radiation alone)

Requirements for participation:

  • High risk bio-chemical recurrence (BCR), defined by rising PSA levels
  • Must be able to receive MRI, CT, or PSMA PET/CT imaging

Not eligible if any of the following apply: 

  • Other cancer diagnosis
  • History of Orchiectomy

Metastatic Hormone Sensitive Prostate Cncer (mHSPC)

Prostate Cancer Treatment (NCT06120491)

Summary: Phase 3 study with second generation PARP inhibitor AZD5305 (Saruparib) in combination with second generation
anti-androgens for patients with newly diagnosed or recurrent metastatic castrate sensitive prostate cancer.

Requirements for participation:

  • Metastatic prostate cancer
  • Ongoing treatment withandrogen depravation therapies

Not eligible if any of the following apply:

  • History of other primary malignancies
  • Previous treatment with PARP inhibitors, second generation anti-androgen therapies, anti-cancer therapies for metastatic prostate cancer

Metastatic Castrate Resistant Prostate Cncer (mCRPC)

Prostate Cancer Treatment (NCT05067140)

Summary: Phase 1/2 study to assess the safety and tolerability of ARV-766 in combination with Abiraterone in patients with metastatic castrate resistant prostate cancer.

Requirements for participation:

  • Cancer progression for castrate resistant prostate cancer after history of treatments (including treatment with second generation androgen inhibitors –NHA)
  • Ongoing treatment with androgen deprivation therapy

Not eligible if any of the following apply:

  • Any other known and active malignancies within the past 3 years
  • Radiation therapy within 4 weeks of study trial enrollment

Prostate Cancer Treatment (NCT06551324)

Summary: Phase 3 study for patients with metastatic castrate resistant prostate cancer with Mevrometostatin combination with Enzalutamide or Enzalutamide alone

Requirements for participation:

  • Failed treatment with Abiraterone Acetate (Zytiga, Yonsa)
  • Rise in PSA and metastasis

Not eligible if any of the following apply:

  • Prior chemotherapy or second-generation anti-cancer therapies

Prostate Cancer Treatment (NCT05075577)

Summary: Phase 1/2 study for patients with metastatic castrate resistant prostate cancer for treatment with Masofanitenin combination with enzalutamide or only enzalutamide.

Requirements for participation:

  • Metastatic prostate cancer
  • Rising PSA levels while on androgen deprivation therapy (ADT)

Not eligible if any of the following apply:

  • Prior treatment with second generation anti-androgens
  • Prior treatment with chemotherapy or other anti-cancer drugs within 1 month of study enrollment
  • Any significant malignancies within 3 years

Bladder Cancer

We offer clinical trials for patients newly diagnosed with bladder cancer and those who have received prior treatments as well. If you fall under one of these categories, please click on the studies below to learn more. Each trial is associated with a National Clinical Trial (NCT) number which links to ClinicalTrials.gov for more information about the study, sponsor, and criteria. All study related medications and tests are covered by Research.

Non-Muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer Treatment (NCT05483868)

Summary: Phase 1 study of belzupacapsarotalocanfollowed by laser for patients with non-muscle invasive bladder cancer who plan to undergo transurethral resection of bladder cancer (TURBT).

Requirements for participation: 

  • Non-muscle invasive bladder cancer
  • Patients must have TURBT scheduled or planned

Not eligible if any of the following apply:

  • Presence of metastatic disease

Bladder Cancer Treatment (NCT06111235)

Summary: Phase 3 study of Cretostimogene Grenadenorepvec versus observation in patients with Intermediate-risk non-muscle invasive bladder Cancer who have had transurethral resection of bladder tumor (TURBT). The study aims to observe and evaluate recurrence free survival.

Requirements for participation: 

  • Transurethral resection of bladder tumor (TURBT) within 12 weeks of starting study

Not eligible if any of the following apply:

  • History of Carcinoma in situ (CIS)
  • History of high-risk non-muscle invasive bladder cancer

Bladder Cancer Treatment (NCT06181266)

Summary: Phase 1/1b study of ZH9 to assess the safety and tolerability of the drug in patients with non-muscle invasive bladder cancer who have had BCG treatment or at least one line of intravesical standard of care treatment.

Requirements for participation: 

  • Non-muscle invasive bladder cancer recurrence after BCG treatment OR one line of standard of care treatment

Not eligible if any of the following apply:

  • Ongoing Urinary Tract Infection (UTI)
  • Other malignancy within 1 year of study enrollment

Bladder Cancer Treatment (NCT04452591)

Summary: Phase 3 study of Cretostimogene Grenadenorepvec for patients with non-muscle invasive bladder cancer who were unresponsive to BCG treatment.

Requirements for participation: 

  • High-grade non-muscle invasive bladder cancer
  • Initial BCG course with at least one round of maintenance therapy

Not eligible if any of the following apply:

  • History of carcinoma in-situ (CIS)
  • History of muscle invasive bladder cancer
  • Prior systemic treatment or radiation therapy for bladder cancer
  • Prior organ transplants

Bladder Cancer Treatment (NCT05014139)

Summary: Phase 1 study of intravesical (within the bladder) enfortumabvedotinfor patients with high-risk non-muscle invasive bladder cancer who are unresponsive to BCG treatment.

Requirements for participation: 

  • High-risk Non-muscle invasive bladder cancer with carcinoma in situ (CIS)
  • BCG unresponsive

Not eligible if any of the following apply:

  • History of muscle invasive bladder cancer
  • Metastasis
  • Prior radiation therapy for bladder cancer

Bladder Cancer Treatment (NCT03945162)

Summary: Phase 2 study aimed at destroying tumor cells through photodynamic therapy in patients with bladder cancer who have failed treatment with BCG.

Requirements for participation: 

  • Non-muscle invasive bladder cancer with carcinoma in situ (CIS)
  • Must have had prior BCG therapy

Not eligible if any of the following apply:

  • Ongoing Urinary Tract Infection (UTI)
  • Metastasis of Bladder Cancer

Muscle Invasive Bladder Cancer (MIBC)

Bladder Cancer Treatment (NCT05316155)

Summary: Phase 1 study of TAR-210 ERDAFITNIB PRETZEL for patients with muscle invasive bladder cancer planning radical cystectomy.

Requirements for participation: 

  • Muscle invasive bladder cancer
  • Willing and eligible to have radical cystectomy
  • Must have FGFR mutation

Not eligible if any of the following apply:

  • Radiotherapy within 6 months of study enrollment
  • Unresolved bladder perforation
  • Historyoractivebladderstoneswithin6monthsofstudyenrollment

Bladder Cancer Treatment (NCT04919512)

Summary: Phase 2 study of TAR-200 in combination with Cetrelimab alone in participants with muscle invasive urothelial carcinoma of the bladder who are scheduled for radical cystectomy and are ineligible for or refusing platinum-based chemotherapy.

Requirements for participation: 

  • Muscle invasive bladder cancer
  • Willing to undergo Radical Cystectomy (RC)
  • Tumors< 3cm after TURBT or no residual tumors

Not eligible if any of the following apply:

  • Received prior systemic chemotherapy, targeted small molecule therapy, or radiation therapy within 2 years prior.

Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hypertrophy Treatment (NCT05400980)

Summary: Study to evaluate the safety and benefits of the UrocrossExpander System and Retrieval Stealth in patients with Benign Prostatic Hyperplasia (BPH).

Requirements: 

  • Men ≥ 45 years at the time of signing the informed consent
  • Willing to temporarily stop all BPH related ongoing medication during study

Not eligible if any of the following apply: 

  • Bladder cancer (including suspected) and/or history of neurogenic bladder

Note to Study Participants

While qualified participants will not be paid for their participation, they will receive all study related medication, visits and tests at no cost depending on requirements of each study individually.